title: [Peptic ulcer disease. Clinical evaluation in 2006].
abstract: Treatment of peptic ulcer disease has undergone a radical change due to the discovery of its main cause, the Helicobacter pylori infection. The management of the chronic infection is now the primary aim. Treatment of peptic ulcer essentially consists of eradicating H. pylori. A current problem is the resistance developed by H. pylori to the antibiotics used in eradication regimen. Ulcers that are induced by nonsteroidal antirheumatic (NSAR) agents and acetylsalicylic acid are gaining in importance. Optimized inhibition of acid secretion with proton pump inhibitors has made it possible to both prevent and cure ulcers in the stomach and duodenum caused by NSAR agents.
authors.affiliation: Klinik für Gastroenterologie, Hepatologie und Infektiologie, Otto-v.-Guericke Universität, Leipziger Strasse 44, 39120 Magdeburg, Germany. peter.malfertheiner@medizin.uni-magdeburg.de
authors.forename: P
authors.initials: P
authors.lastname: Malfertheiner
authors.forename: M
authors.initials: M
authors.lastname: Bellutti
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000628:therapy*; D016480:Helicobacter pylori; D006801:Humans; D010437:Peptic Ulcer / Q000139:chemically induced / Q000175:diagnosis* / Q000628:therapy*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal